Britain and America have secured a important commercial pact that will maintain zero duties on British pharmaceutical exports going into the American market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has pledged to boost spending on medicines through the National Health Service (NHS). This pledge guarantees that tariffs on these key exports will remain at nothing for a timeframe of 36 months.
This deal comes after recent statements to dramatically increase import taxes on patented drug products, with potential rates floated up to double the cost.
"This deal between the UK bolsters the global environment for cutting-edge drugs and introduces long-overdue balance to U.S.–U.K. medicine commerce," a release declared.
Economic Impact
Medicines constitute one of the Britain's largest exports to the US, which is clearly the biggest buyer for leading companies like GSK and AstraZeneca.
Trade data reveal that in the year to the end of the third quarter, the UK shipped medicines worth £11.1bn to the US. This amount represented nearly one-fifth of all goods exports in that timeframe.
"This guarantee secures employment, increases funding and sets the stage for the UK to emerge as a global hub for life sciences," a minister remarked.
Detailed UK Commitments
The pact includes several key pledges from the UK:
- Revised Affordability Limit: The UK will lift the affordability limit at which it judges new treatments to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a aim to increase overall public funding on drugs from 0.3% of GDP to 0.6 percent over the following ten-year period.
- Rebate Cap: The percentage drug companies must return to the NHS to prevent overspending will be restricted at 15%. Previously, refunds were more than twenty percent.
Recent Tensions
This agreement follows a ongoing tension between the drug companies and the UK government over medicine costs and regulatory access.
The disagreement were intensified by claims that American consumers were charged a premium for the identical medicines than patients in the UK and Europe.
Over the last 18 months, several major pharmaceutical investments in the UK have been halted or scrapped, while major expansions have been announced toward projects in the United States.
One official publicly accepted that the NHS had to invest a greater share on treatments, noting that its spending on drugs had shrunk as a proportion of its total funding over the last ten years.
